Buyers widening their own doors: demand already secured, far-side receiving constraint now being cleared
The model's full reasoning — Q4 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否传达了以下情况:公司已经拥有已确定的需求或业务,但交付量受限于对方(客户、合作伙伴等)的接收能力,且对方正在努力解决这个问题,而相关业务大多尚未反映在已报告的结果中。 分析电话会议内容: - 管理层讨论了多个项目,如fazirsiran(AAT)、ARO-APOC3、ARO-ANG3、ARO-C3、肺部项目等。 - 关于fazirsiran,提到SEQUOIA数据已到手,等待FDA反馈,计划与Takeda一起公布数据和Phase 3设计。这里没有明确提到需求已锁定,而是开发阶段。 - 关于ARO-APOC3和ARO-ANG3,提到计划进行Phase 3研究,但尚未开始,也没有提到已获得的需求。 - 关于肺部项目,提到预计在2023年上半年公布中期数据,但仍在临床试验阶段。 - 关于ARO-C3,同样在临床试验中。 - 关于财务,提到出售olpasiran特许权使用费获得资金,但这是融资,不是业务需求。 - 没有提到任何已签订合同、已下单或已承诺的需求,也没有提到对方接收能力受限的情况。 管理层主要谈论的是研发进展、临床试验、监管互动和融资,没有提到“需求已到手但对方无法接收”的情况。因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
MKC · Q2 2018 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive, install, etc., and those counterpartie...**NO** The transcript describes a situation where McCormick has already won shelf-space changes and distribution improvements from retailers (customers have accepted the recommendations), but implementation is delayed due to retailers' own operational reset windows and competitor product sell-through. This is framed as a temporary, ongoing industry practice rather than a binding constraint being actively cleared right now to unlock a meaningfully larger volume of already-secured business. Management presents it as part of their category-management progress with runway ahead, not as counterparties clearing a receiving-side bottleneck that is already underway and will drive the bulk of the upside.
BIIB · Q2 2017 → YESThe question is about whether management conveys that they already have secured demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties are already ...YES The transcript shows management conveying exactly this situation for SPINRAZA. Demand is already secured and arriving: “significant uptake in the U.S.” with “strong demand across patient types” and “roughly two third of patients treated to date having Type 2 or Type 3 SMA.” The binding constraint is on 60% of Type 2 patients who have had spinal surgery, creating intrathecal administration challenges on the receiving side.
BXP · Q1 2022 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties ...YES The transcript shows management conveying secured demand through signed leases totaling over 975,000 square feet on vacant space that have not yet commenced occupancy, plus an additional 1.3 million square feet in active negotiations and over 750,000 square feet in the development pipeline.